Price
15.6
+0%52W Range
Market Cap
₹15.60 Cr
Traded: ₹0.00 Cr (0.00%) 0.0x
Free Float: ₹3.50 Cr (0.02% of FF traded)
Volume · 60D trend
338 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | -- | +14.0% | +23.0% | -- | +69.0% | Accelerating |
| ROE | -- | -- | -- | -- | -- | -- |
| Return | -- | +13.0% | +9.0% | -8.0% | -- | Decelerating |
| Sales | -8.0% | -8.0% | -1.0% | -- | +16.0% | Accelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 3 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| Expenses | 1 | 1 | 2 | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 |
| Operating Profit | -0 | 0 | 1 | -0 | -0 | 0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | 1 |
| OPM % | -30.4% | 21.3% | 29.1% | -24.5% | -6.8% | 2.6% | -2.7% | -11.8% | -22.2% | 32.2% | -6.2% | -9.4% | -40.0% | 45.5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | 0 | 1 | -1 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -1 | 0 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 35.3% | 0.0% | 0.0% | 0.0% | 34.6% | 0.0% | 0.0% | 0.0% | 5600.0% |
| Net Profit | -0 | 0 | 1 | -1 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -1 | -1 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | -0.4 | 0.1 | 0.7 | -0.7 | -0.3 | -0.2 | -0.3 | -0.4 | -0.4 | 0.2 | -0.3 | -0.5 | -0.6 | -0.5 |
| Sales Growth (YoY) | -- | -48.2% | 194.6% | 57.5% | 102.8% | 82.5% | 70.8% | -50.4% | -24.2% | 23.1% | -79.4% | -15.5% | 0.0% | 44.0% |
| Sales Growth (QoQ) | -- | -56.9% | 63.5% | 37.0% | -46.3% | 145.1% | -12.6% | 76.4% | -51.7% | 129.2% | -74.6% | 169.5% | -21.5% | -- |
| OP Growth (YoY) | -180.0% | 328.6% | 3266.7% | -226.7% | 37.5% | -85.4% | 25.0% | 37.5% | 57.9% | -12.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | -193.3% | -68.4% | 293.9% | -390.0% | -242.9% | 333.3% | 80.0% | 6.3% | -133.3% | 1300.0% | 83.3% | 36.8% | -169.1% | -- |
| Profit Growth (YoY) | -- | 122.0% | 350.0% | -100.0% | 16.0% | -235.0% | -4.0% | 25.0% | 39.0% | 131.0% | -35.0% | 14.0% | -39.0% | 76.0% |
| EPS Growth (YoY) | -- | 121.7% | 350.0% | -100.0% | 16.2% | -235.3% | -3.7% | 25.0% | 39.3% | 131.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -92.9% | 197.2% | -132.3% | -34.8% | 17.9% | 22.2% | 2.7% | -317.6% | 163.0% | 43.8% | 21.3% | -13.0% | -- |
| OP Margin | -- | 21.3% | 29.1% | -24.5% | -6.8% | 2.6% | -2.7% | -11.8% | -22.2% | 32.2% | -6.2% | -9.4% | -40.0% | 45.5% |
| Net Margin | -- | 3.5% | 21.4% | -36.0% | -21.2% | -8.5% | -25.2% | -28.4% | -51.4% | 11.4% | -41.5% | -18.8% | -64.2% | -44.6% |
| Material Cost % | -- | 31.2% | 43.4% | 86.0% | 50.0% | 64.7% | 53.1% | 73.2% | 23.6% | 14.8% | 9.2% | 78.9% | 37.9% | -18.2% |
| Employee Cost % | -- | 23.4% | 14.7% | 22.0% | 28.1% | 18.8% | 23.4% | 22.8% | 47.2% | 27.5% | 52.3% | 18.8% | 63.2% | 50.4% |
| P/S | 2.05 | 1.95 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Appointment of Mr. Vimal Dhirendra Shah (DIN: 01506655) as a Managing Director (Promoter and Executive) of the Company for a term of 3 (Three) consecutive years effective from 1st September, ....
Financial Results for the Quarter ended June 30,2026
Board Meeting held on August 14, 2026 for the quarter ended June 30, 2026.
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Outcome of Board Meeting held on Thursday, July 30, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 30 June, 2026.
Intimation for Closure of Trading Window
Appointment of Internal Auditor w.e.f 30.05.2026
As per attachment.
As per attachment.
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve As per attachment.
As per attachment.
As per attachment.
As per attachment
As per attachment.
As per attachment.
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment
As per attachment.
Intimation regarding Order passed by Hon''ble High Court in Criminal Appeal No. 89 of 2020.
As per attachment.
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve As per attachment
As per attachments.
As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per Attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 ,inter alia, to consider and approve As per attachment.
As per attachment.
As per attachment.
As per attachment.
As per attachment.
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 ,inter alia, to consider and approve As per attachment.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
As per attachment.
As per attachment.
As per attachment.